Monopoly in Cancer Drug Pricing

When ProPublica health-care reporter David Armstrong was diagnosed with a rare blood cancer, he began taking a lifesaving drug called Revlimid. When he learned that each pill of this medication is sold for nearly $1,000 but costs drug companies only cents to make, he went on a quest to uncover the reasons behind its shocking price tag. Armstrong sat down with Apple News In Conversation host Shumita Basu to talk about his investigation into Revlimid’s origins and what it reveals about prescription-drug pricing in America.